The Utility of CAPTEM in Chemo-Resistant Neuroendocrine Tumors

April 24, 2014
Robert L. Fine, MD

Robert L. Fine, MD, from Columbia University, comments on the utility of CAPTEM in chemotherapy-resistant neuroendocrine tumors.

Clinical Pearls

Robert L. Fine, MD, associate professor of medicine, Herbert Irving, director, Experimental Therapeutics, medical oncology director, Pancreas Center, Columbia University, comments on the utility of CAPTEM in chemotherapy-resistant neuroendocrine tumors.

  • In a phase II trial, CAPTEM elicited a response rate of 45% and a stable disease rate of 52%.
  • Carcinoids, which represent the majority of all neuroendocrine tumors and typically have a response rate of 0-4%, showed a 45% response rate in this study.
  • CAPTEM was well tolerated: Just 10-15% of patients experienced grade 3 toxicities.